China NMPA accepts BeiGene’s sBLA for tislelizumab in combo with chemotherapy to treat recurrent nasopharyngeal cancer, Health News, ET HealthWorld
Cambridge, Massachusetts : BeiGene announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for anti-PD-1…
